The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in ...

The liver is one of the body’s most vital organs, working tirelessly behind the scenes to detoxify, regulate metabolism, ...

Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa. Phage ...

The Biliary Epigenetics and Regenerative Medicine Lab of Robert C. Huebert, M.D., includes research programs and a biobank containing stem cells from patients with liver disease.

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

Liver endothelial cells respond differentially to various insults, influencing the liver’s niche and disease outcomes. Here the authors show that in response to bile acid chenodeoxycholic acid ...

Secondary sclerosing cholangitis (SSC) is a chronic cholestatic biliary disease, characterized by inflammation, obliterative fibrosis of the bile ducts, stricture formation and progressive ...

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old now impacted by the disease. However, despite this, knowledge about ...

The Saint Louis University Center for Pancreatic and Biliary Diseases has been officially designated ... underlying medical conditions or a significant family history of the disease. At our high-risk ...

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.